Follow the 奥翔药业 share price and the full insider trade history of the company, a listed equity based in China. Shares trade on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 奥翔药业 has recorded 9 public disclosures. Market capitalisation: €6.1bn. The latest transaction was reported on 21 December 2022 (Sale). Among the most active insiders: 刘兵. All data is free.
9
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€29m
9 ops.
Sell Volume
7Σ signal
Buys n/a€29m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,866 of 29,064 companies
47.3
score / 100
Value
34
Quality
61
FCF yld0.9%
Earn yld2.1%
EV/EBITDA29.9x
ROE4.6%
Gross mgn54%
Net mgn16%
Debt/EBITDA2.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.